The analgesic potential of cannabinoids

Journal of Opioid Management

Volumn 5, Issue 6, 2009, Pages 341-357

  Elikottil, Jaseena ^a   Gupta, Pankaj ^a   Gupta, Kalpna ^b  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cannabinoid; Cannabis; Marijuana; Opioid; Pain

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ANANDAMIDE; BUPRENORPHINE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CHLORPROMAZINE; DEXANABINOL; DOMPERIDONE; DRONABINOL; FENTANYL; METOCLOPRAMIDE; MORPHINE; N ARACHIDONYLDOPAMINE; NABILONE; NALOXONE; NALTREXONE; NOLADIN ETHER; OPIATE; PROCHLORPERAZINE; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ANALGESIC AGENT; ANTIEMETIC AGENT; APPETITE STIMULANT; CANNABINOID RECEPTOR; NARCOTIC ANALGESIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANTIEMETIC ACTIVITY; ANTINOCICEPTION; ANXIETY; ATAXIA; CANCER PAIN; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DIARRHEA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHORIA; EUPHORIA; FACE PAIN; FATIGUE; FIBROMYALGIA; HALLUCINATION; HEAD AND NECK CANCER; HEART VENTRICLE BIGEMINY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; INCREASED APPETITE; INFLAMMATORY PAIN; LOW DRUG DOSE; LUNG CANCER; MECHANICAL ALLODYNIA; MOTOR DYSFUNCTION; MOUTH PAIN; MULTIPLE SCLEROSIS; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PROSTATE CANCER; PSYCHOSIS; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIFORM DISORDER; SCIATIC NEUROPATHY; SEDATION; SEIZURE; SENSORY NEUROPATHY; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOKING; SOMNOLENCE; SPASTICITY; SYNCOPE; TACTILE ALLODYNIA; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; ANIMAL; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; PAIN ASSESSMENT;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; ANTIEMETICS; APPETITE STIMULANTS; CANNABINOIDS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HUMANS; PAIN; PAIN MEASUREMENT; RECEPTORS, CANNABINOID; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 75649115024     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0034     Document Type: Review

References (153)

1. Demuth DG, Molleman A: Cannabinoid signalling. Life Sci. 2006; 78(6): 549-563.
2. Booth M: Cannabis: A History, 1st ed. New York: Thomas Dunne Books, 2004.
3. Mikuriya TH: Marijuana in medicine: Past, present and future. Calif Med. 1969; 110(1): 34-40.
4. Zuardi AW: History of cannabis as a medicine: A review. Rev Bras Psiquiatr. 2006; 28(2): 153-157.
5. Brown RT, Zuelsdorff M, Fleming M: Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006; 2(3): 137-146.
6. Davis MP, Lasheen WP, Gamier P: Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know. Oncology (Williston Park). 2007; 21(10): 1229-1238; discussion 1238.
7. Chang G, Chen L, Mao J: Opioid tolerance and hyperalgesia. Med Clin North Am. 2007; 91(2): 199-211.
8. Ballantyne JC, Shin NS: Efficacy of opioids for chronic pain: A review of the evidence. Clin J Pain. 2008; 24(6): 469-478.
9. Svizenska I, Dubovy P, Sulcova A: Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol Biochem Behav. 2008; 90(4): 501-511.
10. Gong JP, Onaivi ES, Ishiguro H, et al.: Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res. 2006; 1071(1): 10-23.
11. Kano M, Ohno-Shosaku T, Hashimotodani Y, et al.: Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009; 89(1): 309-380.
12. Guzman M, Sanchez C, Galve-Roperh I: Control of the cell survival/death decision by cannabinoids. J Mol Med. 2001; 78(11): 613-625.
13. Ryan D, Drysdale AJ, Lafourcade C, et al.: Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009; 29(7): 2053-2063.
14. Howlett AC, Breivogel CS, Childers SR, et al.: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004; 47 (Suppl 1):345-358.
15. Sawzdargo M, Nguyen T, Lee DK, et al.: Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999; 64(2): 193-198.
16. Starowicz K, Nigam S, Di Marzo V: Biochemistry and pharmacology of endovanilloids. Pharmacol Ther. 2007; 114(1): 13-33.
17. Ozaita A, Puighermanal E, Maldonado R: Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem. 2007; 102(4): 1105-1114.
18. Molina-Holgado F, Pinteaux E, Heenan L, et al.: Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci. 2005; 28(1): 189-194.
19. Lee YM, Uhm KO, Lee ES, et al.: AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway. Biochem Biophys Res Commun. 2008; 370(4): 641-645.
20. Greenhough A, Patsos HA, Williams AC, et al.: The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer. 2007; 121(10): 2172-2180.
21. Ellert-Miklaszewska A, Kaminska B, Konarska L: Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 2005; 17(1): 25-37.
22. Caffarel MM, Moreno-Bueno G, Cerutti C, et al.: JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008; 27(37): 5033-5044.
23. Carracedo A, Gironella M, Lorente M, et al.: Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006; 66(13): 6748-6755.
24. Gustafsson K, Christensson B, Sander B, et al.: Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol. 2006; 70(5): 1612-1620.
25. Carracedo A, Lorente M, Egia A, et al.: The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006; 9(4): 301-312.
26. Sarnataro D, Pisanti S, Santoro A, et al.: The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol. 2006; 70(4): 1298-1306.
27. Jeong HJ, Kim SJ, Moon PD, et al.: Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the HEI-OC1 auditory cell line. JNeurosci Res. 2007; 85(4): 896-905.
28. Khasabova IA, Khasabov SG, Harding-Rose C, et al.: A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci. 2008; 28(44): 11141-11152.
29. Hamamoto DT, Giridharagopalan S, Simone DA: Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol. 2007; 558(1-3): 73-87.
30. Elmes SJ, Winyard LA, Medhurst SJ, et al: Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain. 2005; 118(3): 327-335.
31. Quartilho A, Mata HP, Ibrahim MM, et al.: Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology. 2003; 99(4): 955-960.
32. Nackley AG, Makriyannis A, Hohmann AG: Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003; 119(3): 747-757.
33. Siegling A, Hofmann HA, Denzer D, et al.: Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol. 2001; 415(1): R5-R7.
34. Lim G, Sung B, Ji RR, et al.: Upregulation of spinal cannabinoid-1- receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003; 105(1-2): 275-283.
35. Zhang J, Hoffert C, Vu HK, et al.: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci. 2003; 17(12): 2750-2754.
36. Liang YC, Huang CC, Hsu KS: The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology. 2007; 53(1): 169-177.
37. Guindon J, Desroches J, Dani M, et al.: Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. Eur J Pharmacol. 2007; 568(1-3): 173-176.
38. Yamamoto W, Mikami T, Iwamura H: Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol. 2008; 583(1): 56-61.
39. Dogrul A, Gul H, Yildiz O, et al.: Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett. 2004; 368(1): 82-86.
40. Pascual D, Goicoechea C, Suardiaz M, et al.: A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain. 2005; 118(1-2): 23-34.
41. Rahn EJ, Makriyannis A, Hohmann AG: Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol. 2007; 152(5): 765-777.
42. Vera G, Chiarlone A, Cabezos PA, et al.: WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci. 2007; 81(6): 468-479.
43. Rahn EJ, Zvonok AM, Thakur GA, et al.: Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008; 327(2): 584-591.
44. . Comelli F, Giagnoni G, Bettoni I, et al.: Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved. Phytother Res. 2008; 22(8): 1017-1024.
45. Clayton N, Marshall FH, Bountra C, et al.: CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 2002; 96(3): 253-260.
46. Burgos E, Pascual D, Isabel Martin M, et al.: Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. Eur J Pain. 2009 (in press); doi: 10.1016/j.ejpain.2009- 02.003.
47. Kehl LJ, Hamamoto DT, Wacnik PW, et al.: A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 2003; 103(1-2): 175-186.
48. Hanus L, Breuer A, Tchilibon S, et al.: HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999; 96(25): 14228-14233.
49. Guerrero AV, Quang P, Dekker N, et al.: Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett. 2008; 433(2): 77-81.
50. Potenzieri C, Harding-Rose C, Simone DA: The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res. 2008; 1215: 69-75.
51. Smith PA, Selley DE, Sim-Selley LJ, et al.: Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol. 2007; 571(2-3): 129-137.
52. Wilson AR, Maher L, Morgan MM: Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology. 2008; 55(7): 1219-1225.
53. Jan CR, Schneider AS: Sodium-dependent calcium efflux from adrenal chromaffin cells following exocytosis. Possible role of secretory vesicle membranes. J Biol Chem. 1992; 267(14): 9695-9700.
54. Cox ML, Haller VL, Welch SP: Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol. 2007; 567(1-2): 125-130.
55. Cichewicz DL, McCarthy EA: Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003; 304(3): 1010-1015.
56. Smith FL, Cichewicz D, Martin ZL, et al.: The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1998; 60(2): 559-566.
57. Yesilyurt O, Dogrul A, Gul H, et al.: Topical cannabinoid enhances topical morphine antinociception. Pain. 2003; 105(1-2): 303-308.
58. Cichewicz DL, Welch SP, Smith FL: Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Eur J Pharmacol. 2005; 525(1-3): 74-82.
59. Paquette J, Olmstead MC: Ultra-low dose naltrexone enhances cannabinoid-induced antinociception. Behav Pharmacol. 2005; 16(8): 597-603.
60. Crain SM, Shen KF: Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA. 1995; 92(23): 10540-10544.
61. Shen KF, Crain SM: Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 1997; 757(2): 176-190.
62. Williams J, Haller VL, Stevens DL, et al.: Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9- tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol. 2008; 584(1): 78-86.
63. Ibrahim MM, Porreca F, Lai J, et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA. 2005; 102(8): 3093-3098.
64. Ledent C, Valverde O, Cossu G, et al.: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999; 283(5400): 401-404.
65. Castane A, Robledo P, Matifas A, et al.: Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci. 2003; 17(1): 155-159.
66. Naef M, Curatolo M, Petersen-Felix S, et al.: The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003; 105(1-2): 79-88.
67. Seeling W, Kneer L, Buchele B, et al.: Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist. 2006; 55(4): 391-400.
68. Saboory E, Derchansky M, Ismaili M, et al.: Mechanisms of morphine enhancement of spontaneous seizure activity. Anesth Analg. 2007; 105(6): 1729-1735, table of contents.
69. Wallace MJ, Blair RE, Falenski KW, et al.: The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003; 307(1): 129-137.
70. Wallace MJ, Wiley JL, Martin BR, et al.: Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2001; 428(1): 51-57.
71. Blair RE, Deshpande LS, Sombati S, et al.: Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther. 2006; 317(3): 1072-1078.
72. Porreca F, Ossipov MH: Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications, and management options. Pain Med. 2009; 10(4): 654-662.
73. Slatkin NE: Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: Beyond prevention of acute emesis. J Support Oncol. 2007; 5(5 Suppl 3): 1-9.
74. Sontineni SP, Chaudhary S, Sontineni V, et al.: Cannabinoid hyperemesis syndrome: Clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol. 2009; 15(10): 1264-1266.
75. Pattinson KT: Opioids and the control of respiration. Br J Anaesth. 2008; 100(6): 747-758.
76. Gardell LR, King T, Ossipov MH, et al.: Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006; 396(1): 44-49.
77. Chu LF, Angst MS, Clark D: Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008; 24(6): 479-496.
78. Weber ML, Farooqui M, Nguyen J, et al.: Morphine induces mesangial cell proliferation and glomerulopathy via kappa-opioid receptors. Am J Physiol Renal Physiol. 2008; 294(6): F1388-F1397.
79. Arerangaiah R, Chalasani N, Udager AM, et al.: Opioids induce renal abnormalities in tumor-bearing mice. Nephron Exp Nephrol. 2007; 105(3): e80-e89.
80. Pan H, Mukhopadhyay P, Rajesh M, et al.: Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther. 2009; 328(3): 708-714.
81. Gupta K, Kshirsagar S, Chang L, et al.: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002; 62(15): 4491-4498.
82. Bifulco M, Laezza C, Gazzerro P, et al.: Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol Rep. 2007; 17(4): 813-816.
83. Beaulieu P: Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006; 53(8): 769-775.
84. Kraft B, Frickey NA, Kaufmann RM, et al.: Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008; 109(1): 101-110.
85. Beaulieu P, Ware M: Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol. 2007; 20(5): 473-477.
86. Mechoulam R, Hanu L: The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag. 2001; 6(2): 67-73.
87. Davis MP: Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008; 17(1): 85-95.
88. Lane M, Vogel CL, Ferguson J, et al.: Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991; 6(6): 352-359.
89. Kogan NM, Mechoulam R: Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007; 9(4): 413-430.
90. Strasser F, Luftner D, Possinger K, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006; 24(21): 3394-3400.
91. Woolridge E, Barton S, Samuel J, et al.: Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005; 29(4): 358-367.
92. Corless IB, Lindgren T, Holzemer W, et al.: Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009; 18(2): 172-193.
93. Pollmann W, Feneberg W: Current management of pain associated with multiple sclerosis. CNS Drugs. 2008; 22(4): 291-324.
94. Zajicek J, Fox P, Sanders H, et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet. 2003; 362(9395): 1517-1526.
95. Rog DJ, Nurmikko TJ, Friede T, et al.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65(6): 812-819.
96. Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253.
97. Killestein J, Hoogervorst EL, Reif M, et al.: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002; 58(9): 1404-1407.
98. Rog DJ, Nurmikko TJ, Young CA: Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007; 29(9): 2068-2079.
99. Russo EB, Guy GW, Robson PJ: Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabisbased medicine. Chem Biodivers. 2007; 4(8): 1729-1743.
100. Hartrick CT, Kovan JP, Shapiro S: The numeric rating scale for clinical pain measurement: A ratio measure? Pain Pract. 2003; 3(4): 310-316.
101. Galer BS, Jensen MP: Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology. 1997; 48(2): 332-338.
102. Herndon RM: Handbook of Neurological Rating Scales, 2nd ed. New York: Demos Medical Publishing, 2006.
103. Iskedjian M, Bereza B, Gordon A, et al.: Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007; 23(1): 17-24.
104. Maida V, Ennis M, Irani S, et al.: Adjunctive nabilone in cancer pain and symptom management: A prospective observational study using propensity scoring. J Support Oncol. 2008; 6(3): 119-124.
105. Narang S, Gibson D, Wasan AD, et al.: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008; 9(3): 254-264.
106. Holdcroft A, Maze M, Dore C, et al.: A multicenter doseescalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006; 104(5): 1040-1046.
107. Buggy DJ, Toogood L, Marie S, et al.: Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003; 106(1-2): 169-172.
108. Skrabek RQ, Galimova L, Ethans K, et al.: Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008; 9(2): 164-173.
109. Blake DR, Robson P, Ho M, et al., Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006; 45(1): 50-52.
110. Bruera E, Kuehn N, Miller MJ, et al.: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care. 1991; 7(2): 6-9.
111. Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34(3): 672-680.
112. Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007; 68(7): 515-521.
113. Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008; 9(6): 506-521.
114. Nurmikko TJ, Serpell MG, Hoggart B, et al.: Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain. 2007; 133(1-3): 210-220.
115. Frank B, Serpell MG, Hughes J, et al.: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ 2008; 336(7637): 199-201.
116. Notcutt W, Price M, Miller R, et al.: Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia. 2004; 59(5): 440-452.
117. Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain. 2004; 112(3): 299-306.
118. Campbell FA, Tramer MR, Carroll D, et al.: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001; 323(7303): 13-16.
119. Howard J, Anie KA, Holdcroft A, et al.: Cannabis use in sickle cell disease: A questionnaire study. Br J Haematol. 2005; 131(1): 123-128.
120. Ballas SK: Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005; 19(5): 785-802.
121. Smith WR, Penberthy LT, Bovbjerg VE, et al.: Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008; 148(2): 94-101.
122. Shord SS, Chew L, Villano J: Evaluation of opioid induced nausea and vomiting in sickle cell disease. Am J Hematol. 2008; 83(3): 196-199.
123. Burstein SH, Zurier RB: Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009; H(D: 109-119.
124. Nath KA, Grande JP, Croatt AJ, et al.: Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol. 2005; 166(4): 963-972.
125. Montecucco F, Lenglet S, Braunersreuther V, et al.: CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/ reperfusion. J Mol Cell Cardiol. 2009; 46(5): 612-620.
126. Defer N, Wan J, Souktani R, et al.: The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J. 2009; 23(7): 2120-2130.
127. Hillard CJ: Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des. 2008; 14(23): 2347-2361.
128. Zhang M, Martin BR, Adler MW, et al.: Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol. 2009; 4(2): 249-259.
129. Aldington S, Harwood M, Cox B, et al.: Cannabis use and cancer of the head and neck: Case-control study. Otolaryngol Head Neck Surg. 2008; 138(3): 374-380.
130. Aldington S, Harwood M, Cox B, et al.: Cannabis use and risk of lung cancer: A case-control study. Eur Respir J. 2008; 31(2): 280-286.
131. 131- Voirin N, Berthiller J, Benhaim-Luzon V, et al.: Risk of lung cancer and past use of cannabis in Tunisia. J Thorac Oncol. 2006; 1(6): 577-579.
132. Hashibe M, Morgenstern H, Cui Y, et al.: Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006; 15(10): 1829-1834.
133. Bluhm EC, Daniels J, Pollock BH, et al.: Maternal use of recreational drugs and neuroblastoma in offspring: A report from the Children's Oncology Group (United States). Cancer Causes Control. 2006; 17(5): 663-669.
134. Wehner FC, van Rensburg SJ, Thiel PG: Mutagenicity of marijuana and Transkei tobacco smoke condensates in the Salmonella/microsome assay. Mutat Res. 1980; 77(2): 135-142.
135. Busch FW, Seid DA, Wei ET: Mutagenic activity of marihuana smoke condensates. Cancer Lett. 1979; 6(6): 319-324.
136. Van Went GF: Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test. Experientia. 1978; 34(3): 324-325.
137. Zimmerman AM, Stich H, San R: Nonmutagenic action of cannabinoids in vitro. Pharmacology. 1978; 16(6): 333-343.
138. National Toxicology Program: NTP Toxicology and Carcinogenesis Studies of l-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser. 1996; 446:1-317.
139. Chan PC, Sills RC, Braun AG, et al.: Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol. 1996; 30(1): 109-117.
140. McKallip RJ, Lombard C, Fisher M, et al.: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002; 100(2): 627-634.
141. Kogan NM, Blazquez C, Alvarez L, et al.: A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol. 2006; 70(1): 51-59.
142. Galanti G, Fisher T, Kventsel I, et al: Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008; 47(6): 1062-1070.
143. Sarfaraz S, Afaq F, Adhami VM, et al.: Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005; 65(5): 1635-1641.
144. Schneider M: Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008; 13(2): 253-263.
145. Hall W, Degenhardt L: Cannabis use and the risk of developing a psychotic disorder. World Psychiatry. 2008; 7(2): 68-71.
146. Luzi S, Morrison PD, Powell J, et al.: What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res. 2008; 14(2-3): 105-112.
147. Harvey MA, Sellman JD, Porter RJ, et al.: The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev. 2007; 26(3): 309-319.
148. Aragona M, Onesti E, Tomassini V, et al.: Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2008; 32(1): 41-47.
149. Maldonado R: Study of cannabinoid dependence in animals. Pharmacol Ther. 2002; 95(2): 153-164.
150. Hutcheson DM, Tzavara ET, Smadja C, et al.: Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol. 1998; 125(7): 1567-1577.
151. Hasin DS, Keyes KM, Alderson D, et al.: Cannabis withdrawal in the United States: Results from NESARC. J Clin Psychiatry. 2008; 69(9): 1354-1363.
152. DeSanty KP, Dar MS: Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice. Pharmacol Biochem Behav. 2001; 69(1-2): 251-259.
153. Dar MS: Cerebellar CB(1) receptor mediation of delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse. Brain Res. 2000; 864(2): 186-194.